Table 1.

Baseline demographics of 165 subjects whowere treated with 1 of 3 Serotonin Reuptake Inhibitors medications during double-blind clinical trials or open-label extension period of those studies at the Yale Obsessive Compulsive Disorder Clinic.

Baseline demographical and clinical characteristics
	Total	Clomipramine	Fluvoxamine	Fluoxetine
Number	165	62	79	24
Age	35.9±11.0	35.1±10.8	37.2±11.7	34.0±8.9
Gender	69 M	27 M	32 M	10 M
Comorbid diagnosis
Tics	23 (14%)	4 (7%)	14 (18%)	5 (21%)
Major depression  disorder	67 (34%)	15 (24%)	44 (56%)	8 (33%)
Anxiety disorders	26 (16%)	7(11%)	19 (23%)	1 (4%)
Substance abuse	54 (32%)	21 (34%)	25 (32%)	8 (33%)
Trichotillomania	8 (5%)	4 (7%)	4 (5%)	1 (4%)
Eating disorders	13 (8%)	4 (7%)	6 (8%)	3 (13%)
Age of Onset	24.1±8.9	23.1±7.0	25.0±10.3	23.6±7.6
Duration of  illness	14.3±11.7	15.1±10.9	13.5±12.3	14.8±11.6
Y–BOCS score	25.1±5.7 (N=91)	25.1±6.3 (37)	25.7±5.2 (40)	23.9±5.9 (14)
HAM-D score	23.8±12.8 (82)	20.0±12.3 (19)	24.4±12.7 (51)	27.0± 13.4 (12)
Prominent OC symptom dimensions
CW	53 (33%)	28 (45%)	22 (28%)	3 (13%)
AGG/SR	43 (26%)	12 (19%)	24 (30%)	7 (29%)
AGG	29 (18%)	6 (10%)	18 (23%)	5 (21%)
SR	14 (9%)	6 (10%)	6 (8%)	2 (8%)
HRD	5 (3%)	0	5 (6%)	0 (0)
SYM	32 (19%)	13 (21%)	14 (18%)	5 (20.8)
MISC	30 (18.4)	9 (15%)	13 (16%)	8 (33.3)

Y–BOCS: Yale–Brown Obsessive Compulsive Scale, HAM-D: Hamilton Depression Rating Scale, OCD symptom dimensions: CW: cleaning/contamination; AGG/SR=fear of harm, sexual and religious obsessions and checking compulsions (this dimension is subdivided into AGG: fear of harm obsessions and checking compulsions and SR: sexual and religious obsessions and compulsions in posthoc analysis); HRD: hoarding and SYM: ordering, symmetry and arranging obsessions and compulsions.